杜尔瓦卢马布加化疗在晚期胆道癌症:从III期TOPAZ-1研究的3年整体存活率更新
Do-Youn Oh1, Aiwu Ruth He2, Shukui Qin3
1Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Journal of hepatology
|May 17, 2025
概括
杜尔瓦卢马布加上葛西他和西斯 (GemCis) 在晚期胆道癌症 (aBTC) 中表现出持续的整体生存益处. 延长长期幸存者表现出可控的安全性,支持其标准护理地位.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胃肠道瘤学 胃肠道瘤学
背景情况:
- 在TOPAZ-1研究中,评估了杜尔瓦卢马布加体citabine和cisplatin (GemCis) 与安慰剂加体GemCis在晚期胆道癌症 (aBTC) 中.
- 之前的分析显示,使用杜尔瓦卢马布+GemCis.is的整体生存 (OS) 有显著的益处.
研究的目的:
- 报告TOPAZ-1研究中最新的操作系统和安全分析.
- 为了表征延长长期生存者 (eLTS) 和随后的抗癌疗法 (SAT) 使用.
主要方法:
- 有BTC的参与者接受了durvalumab+GemCis或安慰剂+GemCis长达8个周期,随后单一治疗直到疾病进展.
- 评估了OS和严重不良事件 (SAE). eLTS被定义为随机化后 ≥30个月活着的参与者.
主要成果:
- 达尔瓦卢马布+GemCis的中位数是12.9个月,而安慰剂+GemCis的中位数是11.3个月 (HR 0.74).
- 36个月的OS率为14.6%和6.9%. 延长长期存活 (eLTS) 在杜尔瓦卢马布治疗组中更频繁 (17.0%与8.7%相比).
- 杜尔瓦卢马布+GemCis在不考虑SAT使用的情况下改善了OS,SAE在eLTS中可比且较少.
结论:
- 杜尔瓦卢马布+GemCis在aBTC中在随机化后3年表现出持续的生存益处和可管理的安全性概况.
- 所有子组中eLTS的存在支持durvalumab+GemCis作为aBTC的标准第一线治疗.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12.9K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
